托补并用治疗危重症患者肺部感染（气阴两虚、痰热壅肺）疗效的临床观察
|
摘要
研究目的：危重症患者肺部感染是最常见的感染之一,发病率高,病死率亦高。随着细菌耐药率的提高,超级细菌的出现,新一代抗生素研发困难,并且新抗生素的研制并不能从根本上解决问题,使用不久就会产生耐药,治疗肺部感染成为了一个非常棘手的问题,中医药治疗逐渐被大家所重视。本研究通过对西医常规治疗结合中药托毒排脓、攻补兼施治疗危重症患者肺部感染疗效的临床观察,进一步研究中医通过促进排痰对重症患者肺部感染干预性治疗的临床有效性,为改善患者临床症状提供更好的方法并为该方的推广提供一定临床依据。
研究方法：收集38例2010年12月-2011年12月期间入住中国中医科学院西苑医院ICU,符合肺部感染(肺炎)中医辨证属气阴两虚、痰热壅肺证的住院患者,用随机分组对照的临床试验方法将其分为中药加西医常规治疗组(治疗组)19例,西医常规治疗组(对照组)19例,治疗组：中药自拟方(托毒排脓、攻补兼施)加西药常规治疗,对照组：单纯西药常规治疗。治疗一周(7天),分别在治疗第1天、第7天填写CRF表,记录观察监测数据,治疗后,进行治疗组和对照组治疗前后临床疗效、CPIS评分、中医症状评分比较,以及对比白细胞(WBC)计数、中性粒细胞百分比(N%)、C反应蛋白(CRP)、血氧分压、血二氧化碳分压、胸片结果以及排痰量治疗前后的变化。比较两组的疗效何者更具有优势,并客观评价中药自拟方(托毒排脓、攻补兼施)对危重症患者肺部感染干预性治疗的临床疗效。统计数据均采用SPSS17.0统计软件,比较计量资料用t检验或秩和检验(方差不齐时),比较计数资料用Fisher's检验(n<40),用配对样本t检验进行治疗前后的组内比较,独立样本t检验进行治疗后的组间比较。P<0.05有统计学差异。P<0.01具有显著统计学差异。
研究结果：1.治疗后两组的临床疗效比较,治疗组有效率84.2%,对照组有效率66.7%,分析得出治疗组临床疗效较对照组更好；2.治疗后分别进行两组治疗前后中医症状评分的组内比较,P治=0.00(P<0.01),P对=0.00(P<0.01),有显著差异,说明治疗组和对照组均可以显著降低患者中医症状评分；两组治疗后评分比较,P=0.023(P<0.05),有差异,说明治疗组较对照组能更好的改善中医症状评分；3.治疗后分别进行两组CPIS评分治疗前后的组内比较,P治=0.00(P<0.01),P对<0.00(P<0.01),有显著差异,说明治疗组和对照组均可以显著降低患者CPIS评分；两组组间治疗后评分比较,P=0.01(P<0.05),差异有统计学意义；4.经治疗后,两组患者WBC计数、CRP、中性粒细胞百分比、二氧化碳分压、排痰量均下降,血氧分压升高,除WBC计数变化两组间无统计学差异,其余治疗组均优于对照组；5.胸片肺部炎症吸收改善结果两组进行比较分析,P=0.092(P>0.05),统计学无差异。但是治疗组有效率明显高于对照组,认为治疗组在促进肺部炎性吸收方面优于对照组,只是统计无差异。
结论：1.在西医常规治疗的基础上加用中药托毒排脓、攻补兼施治疗危重症患者肺部感染,可以降低肺部感染的严重程度,改善临床症状,有较好的临床治疗效果。2.对于实验室相关指标,虽然对白细胞的变化治疗组较对照组无明显统计学差异,但是中性粒细胞下降趋势治疗组比对照组下降明显,说明此方对降低WBC计数和中性粒细胞有一定的优势。只是统计学上无差异。3.此方可以降低危重症患者肺部感染炎性反应。4.此方有很好的促进痰液排出的效果。
Research purpose:Critically ill patients with pulmonary infection disease are very important and one of the most common infections, high incidence, the mortality is high. With the improvement of resistant bacteria, super bacteria, the emergence of a new generation of antibiotic research difficulties, and the development of new antibiotics and can't fundamentally solve a problem, use will soon produce resistance, the treatment of lung infection became a very difficult problem, traditional Chinese medicine is gradually to attention. By researching the conventional treatment in combination with Chinese traditional medicine to western medicine "row poison attack, for what the sepsis treatment critically ill patients with pulmonary infection disease clinical observation of the curative effect, and further to study TCM by promoting a row of phlegm to critically ill patients lung infection of the clinical effectiveness intervention treatment, to improve the clinical symptoms and provide better method for the promotion of the party to provide certain scientific basis.
Research Method:The data of38cases of December2010-December2011in traditional Chinese medicine academy of sciences in China during the ICU hospital, accord with pulmonary infection (pneumonia) of TCM syndrome differentiation of weak of Qi and Yin, phlegm heat of hospitalized patients with lung card warm, with random grouping antitheses clinical test methods are classified into the western medicine of Chinese medicine for the routine treatment group (treatment group)19cases, western medicine conventional treatment group (control group)19cases, the treatment group:Chinese medicine drafts oneself party (Thomas row poison attack, for what the sepsis) and western medicine conventional treatment group:pure western medicine routine treatment. Treatment for a week (7days), respectively, in the treatment of day1day7days fill in CRF form, record observation monitoring data, after treatment, the treatment group and control group before and after treatment, clinical curative effect of traditional Chinese medicine CPIS score, compared the symptom score, and contrast white blood cells (WBC) counting, neutrophils percentage (N%), c-reactive protein (CRP), blood oxygen partial pressure, blood pressure, chest radiograph carbon dioxide points result and row sputum volume changes before and after treatment. Compared with two groups of curative effect is to have an advantage more, and an objective evaluation of the traditional Chinese medicine to party (Thomas row poison attack, for what the sepsis) to critically ill patients with pulmonary infection disease intervention the clinical efficacy of treatment. Statistical data are used SPSS17.0statistical software, compared with measuring data t test or rank and inspection (variance not neat), more count material with Fisher's inspection (n<40), with matching t test before and after treatment for samples of the comparison in the group, independent t test sample treatment between the group after comparison. P<0.05statistically significant. P<0.01has statistically significant differences.
Research Results:1. After treatment the clinical curative effect of two groups compared, and the effective rate was84.2%in treatment group and control group in the effective rate was66.7%, analysis of the treatment group clinical curative effect is better than control group;2. After treatment are two groups before and after treatment of TCM symptom scores in the group compared to P=0.00(P<0.01), Pto=0.00(P<0.01), there are significant differences, explain treatment group and control group can significantly reduce patients symptom scores of traditional Chinese medicine; The two groups after treating score more,,P=0.023(P<0.05), there is difference between the treatment group, a control group that can improve symptom scores of traditional Chinese medicine;3. After treatment, the two groups CPIS score before and after treatment within the group compared to P=0.00(P<0.01), Pto=0.00(P<0.01), there are significant differences, explain treatment group and control group can be significantly reduced CPIS score patients; Two way after comparison between treatment score, P=0.01(P<0.05), the difference was statistically significant;4. After treatment, the two groups of patients WBC count, CRP, neutrophils percentage, carbon dioxide points pressure, row sputum volume decreased, blood oxygen partial pressure increases, except the WBC count change is no statistical difference between the two groups, and the rest of the treatment group than in control group were;5. Chest radiograph lung inflammation absorption improve results two groups the comparative analysis, F=0.092(P>0.05), there is no difference statistics. But the treatment group efficient obviously is higher than those in the control group, think the treatment group in promoting lung inflammatory absorb is better than control group, but no difference statistics.
Conclusion:1. In the western conventional treatment based on traditional Chinese medicine combined with "row poison attack, for what the sepsis treatment in patients of critical pulmonary infection, reduce the severity of the lung infection, can improve the clinical symptoms, and have a good clinical treatment effect.2. For laboratory, although the change of the white treatment group than the control group no significant difference, but neutrophils down trend treatment group than in the control group down significantly, indicating that this party to reduce the WBC count and neutrophils has certain advantages. Just there was no statistically difference.3. The party can reduce the inflammatory reaction of critically ill patients with pulmonary infection disease.4. The party has a good promote sputum eduction effect.
研究方法：收集38例2010年12月-2011年12月期间入住中国中医科学院西苑医院ICU,符合肺部感染(肺炎)中医辨证属气阴两虚、痰热壅肺证的住院患者,用随机分组对照的临床试验方法将其分为中药加西医常规治疗组(治疗组)19例,西医常规治疗组(对照组)19例,治疗组：中药自拟方(托毒排脓、攻补兼施)加西药常规治疗,对照组：单纯西药常规治疗。治疗一周(7天),分别在治疗第1天、第7天填写CRF表,记录观察监测数据,治疗后,进行治疗组和对照组治疗前后临床疗效、CPIS评分、中医症状评分比较,以及对比白细胞(WBC)计数、中性粒细胞百分比(N%)、C反应蛋白(CRP)、血氧分压、血二氧化碳分压、胸片结果以及排痰量治疗前后的变化。比较两组的疗效何者更具有优势,并客观评价中药自拟方(托毒排脓、攻补兼施)对危重症患者肺部感染干预性治疗的临床疗效。统计数据均采用SPSS17.0统计软件,比较计量资料用t检验或秩和检验(方差不齐时),比较计数资料用Fisher's检验(n<40),用配对样本t检验进行治疗前后的组内比较,独立样本t检验进行治疗后的组间比较。P<0.05有统计学差异。P<0.01具有显著统计学差异。
研究结果：1.治疗后两组的临床疗效比较,治疗组有效率84.2%,对照组有效率66.7%,分析得出治疗组临床疗效较对照组更好；2.治疗后分别进行两组治疗前后中医症状评分的组内比较,P治=0.00(P<0.01),P对=0.00(P<0.01),有显著差异,说明治疗组和对照组均可以显著降低患者中医症状评分；两组治疗后评分比较,P=0.023(P<0.05),有差异,说明治疗组较对照组能更好的改善中医症状评分；3.治疗后分别进行两组CPIS评分治疗前后的组内比较,P治=0.00(P<0.01),P对<0.00(P<0.01),有显著差异,说明治疗组和对照组均可以显著降低患者CPIS评分；两组组间治疗后评分比较,P=0.01(P<0.05),差异有统计学意义；4.经治疗后,两组患者WBC计数、CRP、中性粒细胞百分比、二氧化碳分压、排痰量均下降,血氧分压升高,除WBC计数变化两组间无统计学差异,其余治疗组均优于对照组；5.胸片肺部炎症吸收改善结果两组进行比较分析,P=0.092(P>0.05),统计学无差异。但是治疗组有效率明显高于对照组,认为治疗组在促进肺部炎性吸收方面优于对照组,只是统计无差异。
结论：1.在西医常规治疗的基础上加用中药托毒排脓、攻补兼施治疗危重症患者肺部感染,可以降低肺部感染的严重程度,改善临床症状,有较好的临床治疗效果。2.对于实验室相关指标,虽然对白细胞的变化治疗组较对照组无明显统计学差异,但是中性粒细胞下降趋势治疗组比对照组下降明显,说明此方对降低WBC计数和中性粒细胞有一定的优势。只是统计学上无差异。3.此方可以降低危重症患者肺部感染炎性反应。4.此方有很好的促进痰液排出的效果。
Research purpose:Critically ill patients with pulmonary infection disease are very important and one of the most common infections, high incidence, the mortality is high. With the improvement of resistant bacteria, super bacteria, the emergence of a new generation of antibiotic research difficulties, and the development of new antibiotics and can't fundamentally solve a problem, use will soon produce resistance, the treatment of lung infection became a very difficult problem, traditional Chinese medicine is gradually to attention. By researching the conventional treatment in combination with Chinese traditional medicine to western medicine "row poison attack, for what the sepsis treatment critically ill patients with pulmonary infection disease clinical observation of the curative effect, and further to study TCM by promoting a row of phlegm to critically ill patients lung infection of the clinical effectiveness intervention treatment, to improve the clinical symptoms and provide better method for the promotion of the party to provide certain scientific basis.
Research Method:The data of38cases of December2010-December2011in traditional Chinese medicine academy of sciences in China during the ICU hospital, accord with pulmonary infection (pneumonia) of TCM syndrome differentiation of weak of Qi and Yin, phlegm heat of hospitalized patients with lung card warm, with random grouping antitheses clinical test methods are classified into the western medicine of Chinese medicine for the routine treatment group (treatment group)19cases, western medicine conventional treatment group (control group)19cases, the treatment group:Chinese medicine drafts oneself party (Thomas row poison attack, for what the sepsis) and western medicine conventional treatment group:pure western medicine routine treatment. Treatment for a week (7days), respectively, in the treatment of day1day7days fill in CRF form, record observation monitoring data, after treatment, the treatment group and control group before and after treatment, clinical curative effect of traditional Chinese medicine CPIS score, compared the symptom score, and contrast white blood cells (WBC) counting, neutrophils percentage (N%), c-reactive protein (CRP), blood oxygen partial pressure, blood pressure, chest radiograph carbon dioxide points result and row sputum volume changes before and after treatment. Compared with two groups of curative effect is to have an advantage more, and an objective evaluation of the traditional Chinese medicine to party (Thomas row poison attack, for what the sepsis) to critically ill patients with pulmonary infection disease intervention the clinical efficacy of treatment. Statistical data are used SPSS17.0statistical software, compared with measuring data t test or rank and inspection (variance not neat), more count material with Fisher's inspection (n<40), with matching t test before and after treatment for samples of the comparison in the group, independent t test sample treatment between the group after comparison. P<0.05statistically significant. P<0.01has statistically significant differences.
Research Results:1. After treatment the clinical curative effect of two groups compared, and the effective rate was84.2%in treatment group and control group in the effective rate was66.7%, analysis of the treatment group clinical curative effect is better than control group;2. After treatment are two groups before and after treatment of TCM symptom scores in the group compared to P=0.00(P<0.01), Pto=0.00(P<0.01), there are significant differences, explain treatment group and control group can significantly reduce patients symptom scores of traditional Chinese medicine; The two groups after treating score more,,P=0.023(P<0.05), there is difference between the treatment group, a control group that can improve symptom scores of traditional Chinese medicine;3. After treatment, the two groups CPIS score before and after treatment within the group compared to P=0.00(P<0.01), Pto=0.00(P<0.01), there are significant differences, explain treatment group and control group can be significantly reduced CPIS score patients; Two way after comparison between treatment score, P=0.01(P<0.05), the difference was statistically significant;4. After treatment, the two groups of patients WBC count, CRP, neutrophils percentage, carbon dioxide points pressure, row sputum volume decreased, blood oxygen partial pressure increases, except the WBC count change is no statistical difference between the two groups, and the rest of the treatment group than in control group were;5. Chest radiograph lung inflammation absorption improve results two groups the comparative analysis, F=0.092(P>0.05), there is no difference statistics. But the treatment group efficient obviously is higher than those in the control group, think the treatment group in promoting lung inflammatory absorb is better than control group, but no difference statistics.
Conclusion:1. In the western conventional treatment based on traditional Chinese medicine combined with "row poison attack, for what the sepsis treatment in patients of critical pulmonary infection, reduce the severity of the lung infection, can improve the clinical symptoms, and have a good clinical treatment effect.2. For laboratory, although the change of the white treatment group than the control group no significant difference, but neutrophils down trend treatment group than in the control group down significantly, indicating that this party to reduce the WBC count and neutrophils has certain advantages. Just there was no statistically difference.3. The party can reduce the inflammatory reaction of critically ill patients with pulmonary infection disease.4. The party has a good promote sputum eduction effect.
引文
[1]HilkerR, PoetterC, FinclensenN, eta.l Nosocomial Pnenmonia after acute stroke: implications forneurological intensive caremedicine [J].stroke,2003,34:975-981.
[2]Smith PR.What diagnostic tests are needed for community-acquired pneumonia?Med ClinNorth Am,2001,85:1381-1396.
[3]Misters PA,Weitekamp MR.Community-acquired pneumonia.In:Roger C Bone Pulmonaryand Critical Care Medicine St Louis,MO:Mosbyyear Book,1998,11-16.
[4]Mirrie TJ,Community-acquired pneumonia:epidemiology,etiology,treatment,Infec DisClin of North Am,1998,12:723-740.
[5]Nederman MS,McCombs JS,Unger AN,et al.The cost of treating community-acquiredpneumonia.Clin Ther,1998,20:820-837.
[6]Lim WS,Vticfarlane JT,Boswell TC,et al.Study of community acquired pneumoniaaetiologi (SCAPA)in adults admitted to hospital:implications for managementguidelines. Thorax,2001, 56:296-301.
[7]张蓓燕,白庆瑞,杨郗等.老年人社区获得性肺炎的月罹患率及患者的临床特点分析[J].老年医学与保健,2006,12(4)：241-243.
[8]AmericanThoracic Society. InfectiousDiseasesSociety ofAmerica.Guidelines for the management of adults with hospital acquired,ventilator associated, and healthcare associated pneumonia[J].AmJRespirCritCareMed,2005,171(4):388-416.
[9]胡必杰,何礼贤,张杏怡等.我国医院内肺炎流行病学现状：20世纪90年代发表论文的荟萃分析[J].中华医院感染学杂志,2001,11(3)：177-180.
[10]吴升,郭知学,王选锭.医院获得性肺炎的病原学研究进展[J].医学综述,2009,15(12)：1834-1836.
[11]叶任高,陆再英.内科学[M].北京：人民卫生出版社,2005,5：15.
[12]邰贵刚,张淼.老年肺炎的预防进展[J].中国现代医生,2010,48(5)：36-37.
[13]樊文峰,黄文杰.重症社区获得性肺炎的发病机制.广东医学,2004,25(4)：472-473.
[14]梁颖,习昕,刘双.成人重症社区获得性肺炎的诊治进展[J].中国全科医学,2008,11(6A)：1005-1007.
[15]于小玲,董晓青.油酸型急性呼吸窘迫综合征血清及肺组织促炎症细胞因子变化及山莨菪碱干预的实验研究[J].中国病理生理杂志,2002,18(8)：959.
[16]Cuthbertson BH, GalleyHF, WebsterNR. The effects of nitric oxide and peroxynitrite on interleukin-8 and elastase from lipopolysaccharide-stimulatedwhole blood. AnesthAnalg, 1998,86:427.
[17]朱惠莉,龚瑾,符礼刚.肺部感染时凝血和纤溶系统的变化[J].中国危重病急救医学,2003,15(3)：180-181.
[18]蒋春焕.老年肺部感染患者外周血淋巴细胞表型变化及意义[J].中国煤炭工业医学杂志,2011,14(1)：59-60.
[19]袁瑾豁,杨帆,编译.美国2005《医院获得性肺炎治疗指南》[J].中国感染与化疗杂志,2006,6(6)：420-423.
[20]黄大明.医院获得性肺炎的病原学及危险因素研究进展[J].华夏医学,23(3)：325-328.
[21]李雅立.医院获得性肺炎的危险因素分析及干预措施[J].中国误诊学杂志,2011,11(23)：5645-5646.
[22]沈毅,刘翱,沈瑛.影响下呼吸道医院感染的因素及预防[J].中华医院感染学杂志,2000,10(4)：260-261.
[23]刘青,李忠友.外科疾病并发肺部感染导致呼吸功能不全的病因分析[J].重庆医学,2002,31(11)：1132-1133.
[24]孙小林.ICU病人继发肺部感染的因素及防治[J].中外医疗,2009,15：25.
[25]顾虹.医院获得性肺炎的发病机制与病原学研究进展[J].浙江中西医结合杂志,2008,18(2)：132-133.
[26]武庆平,刘萍,姚尚龙.p-防御素-2在机械通气相关性肺炎发病机制中的作用[J].华中科技大学学报(医学版),2005,34(5)：608-611.
[27]黄宗明,杨婧,揭志刚.医院获得性肺炎的相关病原学与发病机制[J].实用临床医学,2009,10(5)：125-126.
[28]贾巧芝,贾艳梅,刘鹏珍.呼吸机相关性肺炎的发病机制及预防[J].临床肺科杂志,2011,16(4)：603-604.
[29]吴升,郑赞,王选锭.医院获得性肺炎发病机制的研究进展[J].医学综述,2007,13(15)：1141-1143.
[30]徐红冰,归成,刘皋林.社区获得性肺炎病原学分布及药物治疗进展[J].上海医药,2008,29(6)：265-267.
[31]刘又宁,陈民钧,赵铁梅.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1)：3-8.
[32]刘又宁,赵铁梅,姚婉贞等.北京地区成人社区获得性肺炎非典型病原体流行病学调查[J].中华结核和呼吸杂志,2004,27(1)：27-30.
[33]范火召,王素萍,赵启玉.社区获得性肺炎流行特征及病原学分布[J].中国公共卫生,2008,24(7)：825-827.
[34]廖晚珍,彭卫华,胡雪飞.社区获得性肺炎病原谱及药敏谱流行病学的调查[J].江西医药,2009,44(11)：1051-1055.
[36]武莉莉,王健.老年人社区获得性肺炎的临床特点及误诊情况分析[J].临床和实验医学杂志,2011,10(4)：268-269/271.
[36]王云秀,王先定,王富平.医院内老年患者肺部感染的病因分析[J].右江民族医学院学报,2003,3：358-359.
[37]李明,张或.ICU呼吸机相关性肺炎病原菌临床研究[J].临床急诊杂志,2006,7(2)：52-54.
[38]郭晓东,刘亚华,李旭.急诊ICU呼吸衰竭并肺部感染患者的病原学及耐药性分析[J].中华医学感染学杂志,2009,19(23)：3281-3283.
[39]王豪,刘丁,陈萍.重症监护病房呼吸机相关性肺炎感染目标性监测[J].中华医院感染学杂志,2009,19(14)：1850-1852.
[40]Hanes SD,Demirkan K, Tolley E,et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonasmaltophilia incritically ill trauma patients[J]. Clin Infect Dis, 2002,35 (3):228-235.
[41]杨文杰,陶家驹.医院获得性肺炎病原菌耐药性及危险因素分析[J].中华医院感染学杂志,2008,18(4)：586-588.
[42]胡必杰,魏丽,张秀珍,等.医院获得性肺炎发病时间对病原构成影响的回顾性队列研究[J].中华结核和呼吸杂志,2005,28(2)：112-116.
[43]社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10)：651-655.
[44]罗求本,胡尊德.甲泼尼龙联合抗生素治疗重症肺炎的临床研究[J].当代医学,2010,16(14)：77-78.
[45]王蓓,刘雪琴.气道排痰护理的研究进展[J].中国实用护理杂志,2004,20(7)：63-65.
[46]谢春萍,刘灵芝,刘有莲.重症监护病房机械通气病人的振动排痰护理体会[J].全科护理,2010,8(8)：2172-2173.
[47]张杏怡,周新,何礼贤等.经纤维支气管镜采样技术在肺部感染病原学诊断中的应用[J].中国抗感染化疗杂志,2003,3(5)：273-276.
[48]李永华,厉为良,杨玉波.支气管镜对老年重症肺炎抗生素降阶梯治疗的干预[J].临床肺科杂志,200,14(4)：512-513.
[49]洪永青,朱蓉,孟自力.机械通气下纤维支气管镜介入诊治重症肺部感染的临床观察[J].中国呼吸与危重监护杂志,2011,10(3)：237-240.
[50]马强,朱建俊.支气管肺泡灌洗治疗重症肺炎15例[J].临床医学,2009,2(12)：40-41.
[51]陈庆,梁宗安,李凯.重症社区获得性肺炎的预后及激素应用临床探讨[J].华西医学,2008,23(5)：1042-1043.
[52]罗百灵,李秀英,王丽静.影响重症肺炎预后的多个因素分析[J].现代生物医学进展,2009,9(3)：502-504.
[53]易慧,谢灿茂.重症肺炎临床及预后因素分析[J].中华医院感染学杂志,2008,1 8(1)：56-58.
[54]虞抟.医学正传·卷之三·劳极[M].北京：中医古籍出版社,2002.2：186.
[55]孙宗发,俞兴群,聂卫群.益气活血化瘀法治疗重症医院获得性肺炎的研究进展[J].中医学报.2011,163(26)：1423-1425.
[56]赵绍琴.肺炎证治[J].中医杂志,1985,(10)：6.
[57]黄星垣.中医内科急症治疗研究粤探讨.云南中医杂志[J].1981,(1)：22
[58]李建生.老年人社区获得性肺炎中医辨证治疗概要[J].中医学报.2010.148(25)：439-441.
[59]余如瑾,姜良铎,唐光华.成人病毒性肺炎中医临床辨治思路[J].中国中医急症,2004,13(4)：227-228.
[60]孙斌,陈广新,张瑛玉.病毒性肺炎的中医药治疗概况[J].北京中医,2006,25(5)：310-311.
[61]张庆宏.中医药治疗病毒性肺炎临床研究进展[J].中国中医药信息杂志,2007,14(3)：93-95.
[62]李猛,王成祥,徐红日,曹鸿云.正气亏虚、毒瘀互结是老年性肺炎的基本病机[J].中医药临床杂志,2011,23(4)：353-354.
[63]林玉洁,李建军,黄启辉.中医对老年耐药细菌性肺炎的认识[J].广州医药,2010,41(6)：44-47
[64]郭红.中西医结合治疗老年人肺感染88例疗效观察[J].天津中医,1998,(4)：153-154.
[65]洪旭初,陈沁.中西药合用治疗老年肺炎40例[J].实用中医药杂志,1998,(2)：32-33.
[66]高玉龙,陈和平.胸腺肤加复方丹参注射液治疗老年肺炎101例体会[J].实用中西医结合杂志.1996,(1)：6
[67]苗林,王美村,马丽君等.理气冲剂对老年人慢阻肺感染的疗效观察[J].中医药学报,1994,(2)：43-44
[68]余学庆,李建生,王至婉等.肺炎中医证型及症状特征的文献分析[J].上海中医药大学学报,2008,22(2)：26-29.
[69]王海峰,李建生,余学庆等.基于文献的重症肺炎中医证素组合规律研究[J].辽宁中医 杂志,2009,36(12)：2059-2061.
[70]风温肺热病、中风病诊疗标准.山东中医学院学报,1986,10(4)：70-72.
[71]刘卫静,章宏伟,张淑兰等.中医辨证分型结合西医治疗重症肺炎47例疗效观察[J].河北中,2011,33(10)：1502-1505.
[72]马小丽.支楠辨证论治老年人肺炎经验述要[J].陕西中医,2006,27(12)：1554-1555.
[73]王成祥.辨证老年风温肺热55例[J].中国中医急症,1992,l(1)：33-36.
[74]黄崇先.辨证治疗老年人肺炎50例[J].实用中医药杂志,2006,22(4)：218.
[75]魏喜保,艾利民.风温病126例临床分析[J].湖北中医杂志,1984,(6)：16-18.
[76]邹于民.增液汤和血府逐瘀汤治疗风温肺热病52例临床观察[J].中国冶金工业医学杂志,2007,24(3)：338.
[77]林军梅.扶正清肺汤治疗医院获得性老年肺炎33例临床观察[J].浙江中医杂志2007,42(5)：268.
[78]张清,郑艳,郑成铎.加味麻杏石甘汤治疗老年肺炎48例[J].现代医药卫生,2005,21(13)：1711-1712.
[79]杨桦,陈霁虹.合用千金苇茎汤治疗重症肺炎疗效观察[J].浙江中医药大学学报.2011,35(1)：38-39,48.
[80]肖新建,曲立生.双黄连注射液为主治疗老年肺炎32例[J].中国中医急症,2008,17(4)：491.
[81]欧江琴,周泽桂,刘良丽.参芪扶正注射液治疗老年肺炎临床观察[J].贵阳中医学院学报,2006,28(1)：27-28.
[82]李淑云,洪渌.清开灵注射液治疗老年细菌性肺炎30例临床观察[J].中医药临床杂志,2004,16(4)：309.
[83]姚魁武,李建生,马利军等.毒素清口服液对老年人肺炎患者营养状况的影响[J].中国实验方剂学杂志,2003,9(5)：55-57.
[84]韦中.黄芪注射液辅治老年人肺炎的疗效观察[J].现代中西医结合杂志,2003,12(1)：39.
[85]姚亮,宋文宝,杨佩兰.黄芪注射液佐治老年性肺炎疗效观察[J].河南中医,2004,24(11)：33-34.
[86]李冰昱,万启南.鱼腥草注射液治疗老年人肺炎的临床观察[J].国际中医中药杂志,2006,28(3)：151-154.
[87]陆万竹.血必净注射液治疗老年性肺炎36例临床观察[J].中华临床医学研究杂志,2008,14(6)817-818.
[88]万启南,陈晓华,王波.清热解毒扶正颗粒治疗老年人肺炎59例疗效观察[J].光明中 医,2007,22(7)：59-60.
[89]李海顺.痰热清联合头孢哌酮钠治疗脑梗死合并老年性肺炎[J].吉林中医药,2007,27(6)：19.
[90]陈志学,丁国强.痰热清注射液治疗老年肺炎疗效观察[J].中国中医急症,2006,15(2)：130-131.
[91]贾建华.痰热清注射液治疗老年性肺炎疗效观察[J].临床肺科杂志,2007,12(2)：135.
[92]严瑾,荣晓凤,任庆兰等.痰热清注射液治疗老年社区获得性肺炎临床观察[J].中国中医急症,2006,15(7)：698.
[93]倪方平,曹磊磊,杨剑兵.中药足浴佐治重症肺部感染临床研究[J].辽宁中医杂志,1999,26(10)：453-454.
[94]何刚.中药雾化吸入治疗毛细支气管炎临床研究[J].国际医药卫生导报,2005,11(4)：96-97.
[95]赖善中,王燕,罗盛标等.清热解毒液保留灌肠治疗急性感染性疾病240例[J].中国中医急症,2007,16(3)：354-355.
[96]屈冰,杜桂芹,徐立然.“冬病夏治”呼吸道疾病242例[J].中医研究,2007,20(7)：44-45.
[97]杨戈,张杰,姚魁武等.中医药治疗老年人肺炎的临床与实验研究[J].中医药学刊,2003,21(12)：2036-2037.
[98]陈新野,刘明道,邓可斌.托补透脓法治疗慢性鼻窦炎[J].中国中西医结合耳鼻咽唯科杂志,2001,9(5)：251-252.
[2]Smith PR.What diagnostic tests are needed for community-acquired pneumonia?Med ClinNorth Am,2001,85:1381-1396.
[3]Misters PA,Weitekamp MR.Community-acquired pneumonia.In:Roger C Bone Pulmonaryand Critical Care Medicine St Louis,MO:Mosbyyear Book,1998,11-16.
[4]Mirrie TJ,Community-acquired pneumonia:epidemiology,etiology,treatment,Infec DisClin of North Am,1998,12:723-740.
[5]Nederman MS,McCombs JS,Unger AN,et al.The cost of treating community-acquiredpneumonia.Clin Ther,1998,20:820-837.
[6]Lim WS,Vticfarlane JT,Boswell TC,et al.Study of community acquired pneumoniaaetiologi (SCAPA)in adults admitted to hospital:implications for managementguidelines. Thorax,2001, 56:296-301.
[7]张蓓燕,白庆瑞,杨郗等.老年人社区获得性肺炎的月罹患率及患者的临床特点分析[J].老年医学与保健,2006,12(4)：241-243.
[8]AmericanThoracic Society. InfectiousDiseasesSociety ofAmerica.Guidelines for the management of adults with hospital acquired,ventilator associated, and healthcare associated pneumonia[J].AmJRespirCritCareMed,2005,171(4):388-416.
[9]胡必杰,何礼贤,张杏怡等.我国医院内肺炎流行病学现状：20世纪90年代发表论文的荟萃分析[J].中华医院感染学杂志,2001,11(3)：177-180.
[10]吴升,郭知学,王选锭.医院获得性肺炎的病原学研究进展[J].医学综述,2009,15(12)：1834-1836.
[11]叶任高,陆再英.内科学[M].北京：人民卫生出版社,2005,5：15.
[12]邰贵刚,张淼.老年肺炎的预防进展[J].中国现代医生,2010,48(5)：36-37.
[13]樊文峰,黄文杰.重症社区获得性肺炎的发病机制.广东医学,2004,25(4)：472-473.
[14]梁颖,习昕,刘双.成人重症社区获得性肺炎的诊治进展[J].中国全科医学,2008,11(6A)：1005-1007.
[15]于小玲,董晓青.油酸型急性呼吸窘迫综合征血清及肺组织促炎症细胞因子变化及山莨菪碱干预的实验研究[J].中国病理生理杂志,2002,18(8)：959.
[16]Cuthbertson BH, GalleyHF, WebsterNR. The effects of nitric oxide and peroxynitrite on interleukin-8 and elastase from lipopolysaccharide-stimulatedwhole blood. AnesthAnalg, 1998,86:427.
[17]朱惠莉,龚瑾,符礼刚.肺部感染时凝血和纤溶系统的变化[J].中国危重病急救医学,2003,15(3)：180-181.
[18]蒋春焕.老年肺部感染患者外周血淋巴细胞表型变化及意义[J].中国煤炭工业医学杂志,2011,14(1)：59-60.
[19]袁瑾豁,杨帆,编译.美国2005《医院获得性肺炎治疗指南》[J].中国感染与化疗杂志,2006,6(6)：420-423.
[20]黄大明.医院获得性肺炎的病原学及危险因素研究进展[J].华夏医学,23(3)：325-328.
[21]李雅立.医院获得性肺炎的危险因素分析及干预措施[J].中国误诊学杂志,2011,11(23)：5645-5646.
[22]沈毅,刘翱,沈瑛.影响下呼吸道医院感染的因素及预防[J].中华医院感染学杂志,2000,10(4)：260-261.
[23]刘青,李忠友.外科疾病并发肺部感染导致呼吸功能不全的病因分析[J].重庆医学,2002,31(11)：1132-1133.
[24]孙小林.ICU病人继发肺部感染的因素及防治[J].中外医疗,2009,15：25.
[25]顾虹.医院获得性肺炎的发病机制与病原学研究进展[J].浙江中西医结合杂志,2008,18(2)：132-133.
[26]武庆平,刘萍,姚尚龙.p-防御素-2在机械通气相关性肺炎发病机制中的作用[J].华中科技大学学报(医学版),2005,34(5)：608-611.
[27]黄宗明,杨婧,揭志刚.医院获得性肺炎的相关病原学与发病机制[J].实用临床医学,2009,10(5)：125-126.
[28]贾巧芝,贾艳梅,刘鹏珍.呼吸机相关性肺炎的发病机制及预防[J].临床肺科杂志,2011,16(4)：603-604.
[29]吴升,郑赞,王选锭.医院获得性肺炎发病机制的研究进展[J].医学综述,2007,13(15)：1141-1143.
[30]徐红冰,归成,刘皋林.社区获得性肺炎病原学分布及药物治疗进展[J].上海医药,2008,29(6)：265-267.
[31]刘又宁,陈民钧,赵铁梅.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1)：3-8.
[32]刘又宁,赵铁梅,姚婉贞等.北京地区成人社区获得性肺炎非典型病原体流行病学调查[J].中华结核和呼吸杂志,2004,27(1)：27-30.
[33]范火召,王素萍,赵启玉.社区获得性肺炎流行特征及病原学分布[J].中国公共卫生,2008,24(7)：825-827.
[34]廖晚珍,彭卫华,胡雪飞.社区获得性肺炎病原谱及药敏谱流行病学的调查[J].江西医药,2009,44(11)：1051-1055.
[36]武莉莉,王健.老年人社区获得性肺炎的临床特点及误诊情况分析[J].临床和实验医学杂志,2011,10(4)：268-269/271.
[36]王云秀,王先定,王富平.医院内老年患者肺部感染的病因分析[J].右江民族医学院学报,2003,3：358-359.
[37]李明,张或.ICU呼吸机相关性肺炎病原菌临床研究[J].临床急诊杂志,2006,7(2)：52-54.
[38]郭晓东,刘亚华,李旭.急诊ICU呼吸衰竭并肺部感染患者的病原学及耐药性分析[J].中华医学感染学杂志,2009,19(23)：3281-3283.
[39]王豪,刘丁,陈萍.重症监护病房呼吸机相关性肺炎感染目标性监测[J].中华医院感染学杂志,2009,19(14)：1850-1852.
[40]Hanes SD,Demirkan K, Tolley E,et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonasmaltophilia incritically ill trauma patients[J]. Clin Infect Dis, 2002,35 (3):228-235.
[41]杨文杰,陶家驹.医院获得性肺炎病原菌耐药性及危险因素分析[J].中华医院感染学杂志,2008,18(4)：586-588.
[42]胡必杰,魏丽,张秀珍,等.医院获得性肺炎发病时间对病原构成影响的回顾性队列研究[J].中华结核和呼吸杂志,2005,28(2)：112-116.
[43]社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10)：651-655.
[44]罗求本,胡尊德.甲泼尼龙联合抗生素治疗重症肺炎的临床研究[J].当代医学,2010,16(14)：77-78.
[45]王蓓,刘雪琴.气道排痰护理的研究进展[J].中国实用护理杂志,2004,20(7)：63-65.
[46]谢春萍,刘灵芝,刘有莲.重症监护病房机械通气病人的振动排痰护理体会[J].全科护理,2010,8(8)：2172-2173.
[47]张杏怡,周新,何礼贤等.经纤维支气管镜采样技术在肺部感染病原学诊断中的应用[J].中国抗感染化疗杂志,2003,3(5)：273-276.
[48]李永华,厉为良,杨玉波.支气管镜对老年重症肺炎抗生素降阶梯治疗的干预[J].临床肺科杂志,200,14(4)：512-513.
[49]洪永青,朱蓉,孟自力.机械通气下纤维支气管镜介入诊治重症肺部感染的临床观察[J].中国呼吸与危重监护杂志,2011,10(3)：237-240.
[50]马强,朱建俊.支气管肺泡灌洗治疗重症肺炎15例[J].临床医学,2009,2(12)：40-41.
[51]陈庆,梁宗安,李凯.重症社区获得性肺炎的预后及激素应用临床探讨[J].华西医学,2008,23(5)：1042-1043.
[52]罗百灵,李秀英,王丽静.影响重症肺炎预后的多个因素分析[J].现代生物医学进展,2009,9(3)：502-504.
[53]易慧,谢灿茂.重症肺炎临床及预后因素分析[J].中华医院感染学杂志,2008,1 8(1)：56-58.
[54]虞抟.医学正传·卷之三·劳极[M].北京：中医古籍出版社,2002.2：186.
[55]孙宗发,俞兴群,聂卫群.益气活血化瘀法治疗重症医院获得性肺炎的研究进展[J].中医学报.2011,163(26)：1423-1425.
[56]赵绍琴.肺炎证治[J].中医杂志,1985,(10)：6.
[57]黄星垣.中医内科急症治疗研究粤探讨.云南中医杂志[J].1981,(1)：22
[58]李建生.老年人社区获得性肺炎中医辨证治疗概要[J].中医学报.2010.148(25)：439-441.
[59]余如瑾,姜良铎,唐光华.成人病毒性肺炎中医临床辨治思路[J].中国中医急症,2004,13(4)：227-228.
[60]孙斌,陈广新,张瑛玉.病毒性肺炎的中医药治疗概况[J].北京中医,2006,25(5)：310-311.
[61]张庆宏.中医药治疗病毒性肺炎临床研究进展[J].中国中医药信息杂志,2007,14(3)：93-95.
[62]李猛,王成祥,徐红日,曹鸿云.正气亏虚、毒瘀互结是老年性肺炎的基本病机[J].中医药临床杂志,2011,23(4)：353-354.
[63]林玉洁,李建军,黄启辉.中医对老年耐药细菌性肺炎的认识[J].广州医药,2010,41(6)：44-47
[64]郭红.中西医结合治疗老年人肺感染88例疗效观察[J].天津中医,1998,(4)：153-154.
[65]洪旭初,陈沁.中西药合用治疗老年肺炎40例[J].实用中医药杂志,1998,(2)：32-33.
[66]高玉龙,陈和平.胸腺肤加复方丹参注射液治疗老年肺炎101例体会[J].实用中西医结合杂志.1996,(1)：6
[67]苗林,王美村,马丽君等.理气冲剂对老年人慢阻肺感染的疗效观察[J].中医药学报,1994,(2)：43-44
[68]余学庆,李建生,王至婉等.肺炎中医证型及症状特征的文献分析[J].上海中医药大学学报,2008,22(2)：26-29.
[69]王海峰,李建生,余学庆等.基于文献的重症肺炎中医证素组合规律研究[J].辽宁中医 杂志,2009,36(12)：2059-2061.
[70]风温肺热病、中风病诊疗标准.山东中医学院学报,1986,10(4)：70-72.
[71]刘卫静,章宏伟,张淑兰等.中医辨证分型结合西医治疗重症肺炎47例疗效观察[J].河北中,2011,33(10)：1502-1505.
[72]马小丽.支楠辨证论治老年人肺炎经验述要[J].陕西中医,2006,27(12)：1554-1555.
[73]王成祥.辨证老年风温肺热55例[J].中国中医急症,1992,l(1)：33-36.
[74]黄崇先.辨证治疗老年人肺炎50例[J].实用中医药杂志,2006,22(4)：218.
[75]魏喜保,艾利民.风温病126例临床分析[J].湖北中医杂志,1984,(6)：16-18.
[76]邹于民.增液汤和血府逐瘀汤治疗风温肺热病52例临床观察[J].中国冶金工业医学杂志,2007,24(3)：338.
[77]林军梅.扶正清肺汤治疗医院获得性老年肺炎33例临床观察[J].浙江中医杂志2007,42(5)：268.
[78]张清,郑艳,郑成铎.加味麻杏石甘汤治疗老年肺炎48例[J].现代医药卫生,2005,21(13)：1711-1712.
[79]杨桦,陈霁虹.合用千金苇茎汤治疗重症肺炎疗效观察[J].浙江中医药大学学报.2011,35(1)：38-39,48.
[80]肖新建,曲立生.双黄连注射液为主治疗老年肺炎32例[J].中国中医急症,2008,17(4)：491.
[81]欧江琴,周泽桂,刘良丽.参芪扶正注射液治疗老年肺炎临床观察[J].贵阳中医学院学报,2006,28(1)：27-28.
[82]李淑云,洪渌.清开灵注射液治疗老年细菌性肺炎30例临床观察[J].中医药临床杂志,2004,16(4)：309.
[83]姚魁武,李建生,马利军等.毒素清口服液对老年人肺炎患者营养状况的影响[J].中国实验方剂学杂志,2003,9(5)：55-57.
[84]韦中.黄芪注射液辅治老年人肺炎的疗效观察[J].现代中西医结合杂志,2003,12(1)：39.
[85]姚亮,宋文宝,杨佩兰.黄芪注射液佐治老年性肺炎疗效观察[J].河南中医,2004,24(11)：33-34.
[86]李冰昱,万启南.鱼腥草注射液治疗老年人肺炎的临床观察[J].国际中医中药杂志,2006,28(3)：151-154.
[87]陆万竹.血必净注射液治疗老年性肺炎36例临床观察[J].中华临床医学研究杂志,2008,14(6)817-818.
[88]万启南,陈晓华,王波.清热解毒扶正颗粒治疗老年人肺炎59例疗效观察[J].光明中 医,2007,22(7)：59-60.
[89]李海顺.痰热清联合头孢哌酮钠治疗脑梗死合并老年性肺炎[J].吉林中医药,2007,27(6)：19.
[90]陈志学,丁国强.痰热清注射液治疗老年肺炎疗效观察[J].中国中医急症,2006,15(2)：130-131.
[91]贾建华.痰热清注射液治疗老年性肺炎疗效观察[J].临床肺科杂志,2007,12(2)：135.
[92]严瑾,荣晓凤,任庆兰等.痰热清注射液治疗老年社区获得性肺炎临床观察[J].中国中医急症,2006,15(7)：698.
[93]倪方平,曹磊磊,杨剑兵.中药足浴佐治重症肺部感染临床研究[J].辽宁中医杂志,1999,26(10)：453-454.
[94]何刚.中药雾化吸入治疗毛细支气管炎临床研究[J].国际医药卫生导报,2005,11(4)：96-97.
[95]赖善中,王燕,罗盛标等.清热解毒液保留灌肠治疗急性感染性疾病240例[J].中国中医急症,2007,16(3)：354-355.
[96]屈冰,杜桂芹,徐立然.“冬病夏治”呼吸道疾病242例[J].中医研究,2007,20(7)：44-45.
[97]杨戈,张杰,姚魁武等.中医药治疗老年人肺炎的临床与实验研究[J].中医药学刊,2003,21(12)：2036-2037.
[98]陈新野,刘明道,邓可斌.托补透脓法治疗慢性鼻窦炎[J].中国中西医结合耳鼻咽唯科杂志,2001,9(5)：251-252.